Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTX 
BioNTech SE (BNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BNTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $137.72
1 Year Target Price $137.72
| 13 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.49% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.03B USD | Price to earnings Ratio - | 1Y Target Price 137.72 |
Price to earnings Ratio - | 1Y Target Price 137.72 | ||
Volume (30-day avg) 21 | Beta 1.28 | 52 Weeks Range 76.53 - 131.49 | Updated Date 07/3/2025 |
52 Weeks Range 76.53 - 131.49 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.89% | Operating Margin (TTM) -270.46% |
Management Effectiveness
Return on Assets (TTM) -3.67% | Return on Equity (TTM) -3.94% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 9740166575 | Price to Sales(TTM) 9.48 |
Enterprise Value 9740166575 | Price to Sales(TTM) 9.48 | ||
Enterprise Value to Revenue 2.99 | Enterprise Value to EBITDA 110.81 | Shares Outstanding 240395008 | Shares Floating 97284490 |
Shares Outstanding 240395008 | Shares Floating 97284490 | ||
Percent Insiders 62.69 | Percent Institutions 22.24 |
Upturn AI SWOT
BioNTech SE
Company Overview
History and Background
BioNTech SE was founded in 2008 in Mainz, Germany, by Uu011fur u015eahin and u00d6zlem Tu00fcreci. Initially focused on cancer immunotherapy, it gained prominence during the COVID-19 pandemic through the development and commercialization of the mRNA-based COVID-19 vaccine in partnership with Pfizer.
Core Business Areas
- Human Pharma Oncology: Development of individualized cancer immunotherapies based on mRNA and other platforms.
- Human Pharma Infectious Diseases: Development of vaccines and immunotherapies against infectious diseases, including COVID-19, influenza, and malaria.
- Animal Health: Development of mRNA-based therapies for animal diseases.
- Research and Development: Ongoing research into new mRNA technologies and applications.
Leadership and Structure
Uu011fur u015eahin (CEO) and u00d6zlem Tu00fcreci (CMO) lead BioNTech SE. The company has a structured organizational framework with dedicated teams for R&D, manufacturing, and commercial operations. It operates globally with key facilities in Germany and the US.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): mRNA-based vaccine developed in partnership with Pfizer. Significant revenue generated during the pandemic. Competitors: Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ).
- OncoRNA platform: Platform for developing mRNA-based cancer therapies. Still in clinical trials. Competitors: Moderna (MRNA), CureVac (CVAC).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. mRNA technology has emerged as a promising field with potential applications in various diseases.
Positioning
BioNTech is a leading player in mRNA technology, with a strong focus on cancer immunotherapy and infectious diseases. The company has a competitive advantage through its established partnerships and innovative technology platforms.
Total Addressable Market (TAM)
The global vaccine market is expected to reach $100 billion by 2025. The cancer immunotherapy market is projected to reach $177 billion by 2028. BioNTech is positioned to capture a significant share of these markets with its mRNA technology.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology
- Successful COVID-19 vaccine development
- Strong partnerships (Pfizer)
- Experienced leadership team
- Robust R&D pipeline
Weaknesses
- Reliance on COVID-19 vaccine revenue
- High R&D expenses
- Regulatory risks
- Manufacturing complexity
- Competition in mRNA space
Opportunities
- Expansion into new therapeutic areas (cancer, infectious diseases)
- Development of personalized cancer vaccines
- Strategic acquisitions and collaborations
- Geographic expansion
- Application of mRNA technology to animal health
Threats
- Decreasing COVID-19 vaccine demand
- Competition from other mRNA companies
- Patent disputes
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- NVO
Competitive Landscape
BioNTech's competitive advantage lies in its expertise in mRNA technology and its strategic partnerships. However, it faces increasing competition from other established pharmaceutical companies and emerging biotech firms.
Major Acquisitions
InstaDeep
- Year: 2023
- Acquisition Price (USD millions): 560
- Strategic Rationale: To integrate artificial intelligence and machine learning capabilities into BioNTech's drug discovery and development processes.
Growth Trajectory and Initiatives
Historical Growth: Rapid growth driven by COVID-19 vaccine sales. Future growth depends on expanding its pipeline and securing new revenue streams.
Future Projections: Analyst estimates vary depending on the success of their cancer immunotherapy programs and infectious disease vaccines.
Recent Initiatives: Acquisition of InstaDeep, expansion of manufacturing capacity, collaborations for new mRNA therapies.
Summary
BioNTech is a pioneering company with a successful mRNA platform, particularly evident in its COVID-19 vaccine. While facing decreased vaccine demand, its strong R&D pipeline focused on cancer immunotherapy and infectious diseases offers growth potential. Intense competition and regulatory risks are factors to watch. Its financial health and future success depend on its ability to diversify its revenue streams.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioNTech SE Investor Relations
- Company Press Releases
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial professional. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNTech SE
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6772 | Website https://www.biontech.de |
Full time employees 6772 | Website https://www.biontech.de | ||
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.